Literature DB >> 9324115

Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension.

Y Nakano1, T Oshima, M Watanabe, H Matsuura, G Kajiyama, M Kambe.   

Abstract

Insertion/deletion (I/D) polymorphism of the angiotensin converting enzyme (ACE) gene has been shown to be a determinant for serum ACE level and a marker for several cardiovascular diseases. We investigated whether the ACE gene can predict the therapeutic efficacy of ACE inhibitors in essential hypertensive patients. The response of blood pressure and plasma renin activity (PRA) 1 h after 50 mg captopril administration were evaluated in 82 inpatients with untreated essential hypertension (42 men, 40 women; mean age +/- SD: 52 +/- 13 years; range: 27 to 79 years) in relation to ACE genotypes. There were no differences in age, gender, blood pressure, and PRA in the basal conditions, among essential hypertensive patients with the II, ID, and DD genotypes (n = 36, 34, and 12, respectively). The acute responses of PRA and blood pressure to an ACE inhibitor were similar in the three groups. The blood pressure response was negatively correlated with baseline PRA (r = 0.497). These data suggest that PRA but not the I/D polymorphism of the ACE gene is a useful predictor of the short-term antihypertensive effects of ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9324115     DOI: 10.1016/s0895-7061(97)00279-3

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

Review 1.  Angiotensin I-converting enzyme: genotype and disease associations.

Authors:  D Crisan; J Carr
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

Review 2.  Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.

Authors:  Tianhua Niu; Xiu Chen; Xiping Xu
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Gene markers and antihypertensive therapy.

Authors:  Stephen T Turner; Gary L Schwartz
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

4.  Pharmacogenetics of cardiovascular drug therapy.

Authors:  Bas J M Peters; Olaf H Klungel; Anthonius de Boer; Bruno H Ch Stricker; Anke-Hilse Maitland-van der Zee
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 5.  Genetics of arterial hypertension and hypotension.

Authors:  Dieter Rosskopf; Markus Schürks; Christian Rimmbach; Rafael Schäfers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-30       Impact factor: 3.000

Review 6.  Keeping pace with ACE: are ACE inhibitors and angiotensin II type 1 receptor antagonists potential doping agents?

Authors:  Pei Wang; Matthew N Fedoruk; Jim L Rupert
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

7.  ACE genotype, risk and causal relationship to stroke: implications for treatment.

Authors:  Agnieszka Slowik; Tomasz Dziedzic; Joanna Pera; Dorota Wloch; Grzegorz Kopec; Andrzej Szczudlik
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-06

8.  What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review.

Authors:  M Scharplatz; M A Puhan; J Steurer; L M Bachmann
Journal:  BMC Med Genet       Date:  2004-09-10       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.